Has Indegene declared dividend?

Indegene Ltd has declared a 100% dividend with an ex-date of June 13, 2025. However, the dividend yield is 0%, and total returns over longer periods show no growth, indicating mixed performance.

Indegene Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Ex-date: 13 Jun 25<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, Indegene experienced a price return of -6.36%, a dividend return of 0.34%, resulting in a total return of -6.02%.<BR><BR>Over the past year, the company achieved a price return of 9.98%, a dividend return of 0.36%, leading to a total return of 10.34%.<BR><BR>For the 2-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 3-year period, Indegene reported no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Similarly, over the last 4 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>In the 5-year period, the company again had no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, while Indegene has declared a dividend, the dividend yield remains at 0%, and the total returns over longer periods show no growth, indicating a mixed performance in terms of returns.

Who are the peers of the Indegene?

Indegene's peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, and others, with varying management risks and growth rates. Suven Life Scie. has the highest 1-year return at 161.32%, while Indegene's return is 16.62%.

Peers: The peers of Indegene are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., Suven Life Scie., Laxmi Dental, Vimta Labs, and Krsnaa Diagnost.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs and Laxmi Dental, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and Vimta Labs, and the rest. Below Average management risk is present at Suven Life Scie. and Krsnaa Diagnost. Growth is Excellent at Laxmi Dental, Average at Poly Medicure, Indegene, and Vimta Labs, while Below Average growth is noted at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and Suven Life Scie., and the rest. Capital Structure is Excellent at Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and Krsnaa Diagnost., while Good is found at Laxmi Dental, Average at Vimta Labs, and Below Average at Suven Life Scie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Suven Life Scie. at 161.32%, while the lowest is Metropolis Healt at -11.47%. Indegene's own 1-year return is 16.62%, which is significantly higher than Metropolis Healt but lower than Suven Life Scie. Additionally, the peers with negative six-month returns include Syngene Intl., Poly Medicure, Metropolis Healt, and Krsnaa Diagnost.

Is Indegene overvalued or undervalued?

As of June 17, 2025, Indegene is considered undervalued with an attractive valuation grade, reflected by a PE ratio of 34.27, an EV to EBITDA of 23.16, and a strong ROCE of 43.13%, despite its higher ratios compared to peers like TCS and Infosys and a year-to-date return of -3.89% versus the Sensex's 4.41%.

As of 17 June 2025, the valuation grade for Indegene has moved from fair to attractive, indicating a more favorable outlook for the company. The current analysis suggests that Indegene is undervalued. Key ratios include a PE ratio of 34.27, an EV to EBITDA of 23.16, and a ROCE of 43.13%, which reflects strong operational efficiency.<BR><BR>In comparison to peers, Indegene's PE ratio is notably higher than TCS at 26.2 and Infosys at 25.51, while its EV to EBITDA is also above TCS's 18.32. This suggests that while Indegene is trading at a premium compared to some peers, its robust ROCE and PEG ratio of 0.00 indicate significant growth potential. Despite recent stock performance trailing the Sensex, with a YTD return of -3.89% compared to the Sensex's 4.41%, the overall valuation metrics support the conclusion that Indegene is currently undervalued.

What does Indegene do?

Indegene Ltd is a mid-cap healthcare services company, incorporated in 1998, with recent net sales of ₹7,556 Cr and a net profit of ₹1,176 Cr as of March 2025. It has a market cap of ₹13,983 Cr and key metrics include a P/E ratio of 34.00 and a dividend yield of 0.35%.

Overview:<BR>Indegene Ltd operates in the healthcare services industry and is categorized as a mid-cap company.<BR><BR>History:<BR>Indegene Limited was incorporated in 1998 as Indegene Lifesystems Private Limited. The company underwent several name changes, becoming Indegene Private Limited in 2016 and then Indegene Limited after converting to a public company in 2022. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 7,556 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 1,176 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 13,983 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 34.00 <BR>Industry P/E: 29 <BR>Dividend Yield: 0.35% <BR>Debt-Equity: -0.60 <BR>Return on Equity: 15.55% <BR>Price to Book: 5.29 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the top shareholders of the Indegene?

The top shareholders of Indegene include Nadathur Fareast Pte Ltd with 21.96%, 18 mutual fund schemes holding 2.65%, and 72 foreign institutional investors owning 5.24%. Individual investors hold 11.34%, with no pledged promoter holdings or a single dominant promoter.

The top shareholders of Indegene include Nadathur Fareast Pte Ltd, which holds the largest public share at 21.96%. Additionally, the company has a diverse shareholder base with 18 mutual fund schemes collectively holding 2.65% and 72 foreign institutional investors (FIIs) holding 5.24%. Individual investors also have a significant presence, owning 11.34% of the shares. Notably, there are no pledged promoter holdings, and there isn't a single promoter with the highest holding.

How big is Indegene?

As of 24th July, Indegene Ltd has a market capitalization of 13,564.00 Cr, with recent Net Sales of 2,839.30 Cr and a Net Profit of 406.70 Cr. The company has Shareholder's Funds of 2,615.60 Cr and Total Assets of 3,236.10 Cr.

As of 24th July, Indegene Ltd has a market capitalization of 13,564.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, Indegene reported Net Sales of 2,839.30 Cr and a Net Profit of 406.70 Cr.<BR><BR>For the reporting period of March 2025, the company has Shareholder's Funds amounting to 2,615.60 Cr and Total Assets of 3,236.10 Cr.

When is the next results date for Indegene?

Indegene will announce its results on 30 October 2025.

Indegene will declare its results on 30 October 2025.

Are Indegene latest results good or bad?

Indegene's latest results show strong revenue growth of 17.09% year-on-year, reaching ₹804.20 crores, but a 12.29% decline in net profit and a significant drop in operating margin raise concerns about operational efficiency and cost management. Investors should watch how the company addresses these challenges moving forward.

Indegene's latest results present a mixed picture. On one hand, the company achieved robust revenue growth of 17.09% year-on-year, reaching ₹804.20 crores, which is the highest quarterly sales figure on record. This indicates strong demand and effective market positioning.<BR><BR>However, the sequential net profit declined by 12.29% from the previous quarter, falling to ₹102.10 crores. This profit drop, despite the revenue increase, raises concerns about operational efficiency and cost management, particularly as the operating margin contracted significantly to 17.48% from 20.41% in the prior quarter. The increase in employee costs, which outpaced revenue growth, suggests potential challenges in managing operational expenses.<BR><BR>Overall, while the revenue growth is a positive sign, the decline in profitability and margin compression are concerning factors that could impact the company's near-term performance. Investors should closely monitor how Indegene addresses these margin pressures in the upcoming quarters.

How has been the historical performance of Indegene?

Indegene has demonstrated consistent financial growth over the past four years, with net sales increasing from 1,664.61 Cr in March 2022 to 2,839.30 Cr in March 2025, alongside significant rises in operating profit and net profit. The company has also reduced its total debt to zero by March 2025, indicating strong overall performance.

Answer:<BR>Indegene has shown a consistent growth trajectory in its financial performance over the past four years, with significant increases in net sales, operating profit, and net profit.<BR><BR>Breakdown:<BR>Indegene's net sales have risen from 1,664.61 Cr in March 2022 to 2,839.30 Cr in March 2025, reflecting a robust growth trend. Total operating income has mirrored this increase, reaching 2,839.30 Cr in March 2025, up from 1,664.61 Cr in March 2022. The company's operating profit (PBDIT) also demonstrated substantial growth, climbing from 312.81 Cr in March 2022 to 641.50 Cr in March 2025. Profit before tax followed suit, increasing from 226.50 Cr in March 2022 to 539.30 Cr in March 2025, while profit after tax rose from 162.82 Cr to 406.70 Cr in the same period. The company's total assets have expanded significantly, from 1,284.31 Cr in March 2022 to 3,236.10 Cr in March 2025, alongside a reduction in total debt, which dropped to 0.00 Cr in March 2025 from 403.10 Cr in March 2024. Cash flow from operating activities has also been positive, amounting to 441.00 Cr in March 2025, although cash flow from investing activities was negative at -677.00 Cr. Overall, Indegene's financial metrics indicate a strong and improving performance over the years.

Should I buy, sell or hold Indegene?

Is Indegene technically bullish or bearish?

As of December 1, 2025, the technical trend is mildly bearish due to bearish momentum from the MACD and KST, daily moving averages, and Bollinger Bands, despite conflicting signals from Dow Theory and a lack of momentum indicated by the RSI.

As of 1 December 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, primarily driven by the weekly MACD and KST both indicating bearish momentum, along with daily moving averages also showing a bearish trend. The Bollinger Bands on the weekly chart confirm a bearish outlook, while the Dow Theory indicates a mildly bullish stance on the weekly timeframe, suggesting some conflicting signals. The RSI shows no signal on both weekly and monthly timeframes, indicating a lack of momentum. Overall, the indicators suggest a cautious approach as the stock remains below its previous close and has a significant decline over the past year.

Which are the latest news on Indegene?

Why is Indegene falling/rising?

As of 03-Dec, Indegene Ltd's stock price is Rs 523.90, down 1.29%, and has underperformed its sector today. The stock has declined 13.26% year-to-date, with decreasing investor participation and a bearish trend indicated by trading below key moving averages.

As of 03-Dec, Indegene Ltd's stock price is falling, currently at Rs 523.90, reflecting a decrease of Rs 6.85 or 1.29%. The stock has underperformed its sector by 2.16% today and has touched an intraday low of Rs 518, which is a decline of 2.4%. Over the past month, the stock has decreased by 2.30%, while the benchmark Sensex has increased by 1.34%. Year-to-date, Indegene's stock has fallen by 13.26%, contrasting sharply with the Sensex's gain of 8.92%.<BR><BR>Investor participation appears to be declining, as evidenced by a 1.89% drop in delivery volume compared to the 5-day average. Although the stock is liquid enough for trading, it is currently trading below its 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Despite some positive factors, such as high management efficiency and increasing institutional investor participation, these have not been sufficient to counteract the current downward pressure on the stock price.